CompletedPhase 1NCT03020602
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Seema Nagpal
- Principal Investigator
- Seema NagpalStanford University
- Intervention
- Laboratory Biomarker Analysis(other)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2021
Study locations (1)
- Stanford University, School of Medicine, Palo Alto, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03020602 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07301268GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 AstrocytomaMayo Clinic
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center